Erasca Announces Proposed Public Offering of $500 Million of Common Stock
Rhea-AI Summary
Erasca (Nasdaq: ERAS) announced a proposed underwritten public offering of $500 million of its common stock, with all shares to be sold by the company. Erasca also plans to grant underwriters a 30-day option to purchase up to an additional $75 million of common stock.
According to Erasca, net proceeds, together with existing cash, cash equivalents, and marketable securities, are expected to fund research and development of its product candidates, other development programs, and general corporate purposes. J.P. Morgan, Morgan Stanley, Jefferies, and Evercore ISI are joint book-running managers. The offering will be made under an effective Form S-3 shelf registration statement.
Positive
- $500 million primary equity capital targeted for R&D and corporate needs
- Potential additional capital via $75 million underwriter option
- Use of proceeds directed to advancing oncology product candidates and programs
Negative
- Proposed common stock sale of $500 million implies future shareholder dilution
- Actual size and timing of the offering remain uncertain and subject to market conditions
News Explained
The disclosure creates potential common-stock dilution, but the $500 million financing remains proposed rather than completed.
The July 13 release says Erasca intends to sell
If issued, the additional shares would increase total share count and reduce existing holders’ percentage ownership, absent offsetting changes.
The underwriters may receive an option for up to
Here, an underwritten offering means an investment bank buys securities from the issuer and resells them, with fees reducing net proceeds below gross proceeds.
The effective Form S-3 shelf authorizes future sales capacity but does not itself sell shares; the release says a preliminary prospectus supplement will be filed for this offering.
On the disclosed figures, the proposed gross amount equals
The release identifies research and development, working capital, and other general corporate purposes as intended uses of net proceeds, so eventual proceeds would be net of underwriting fees and could differ from the proposed gross amount.
The final size, price, and fees belong in the offering prospectus supplement rather than being inferred from the effective shelf registration.
Sources and calculations
- July 13 Erasca proposed public offering release (2026-07-13)
- Dilution definition (undated)
- Underwritten offering definition (undated)
- Form S-3 purpose (undated)
- Prospectus supplement purpose (undated)
- Erasca Form S-3ASR filing (2026-07-13)
- Erasca first-quarter 2026 fundamentals (2026Q1)
- Offering gross vs quarterly operating cash outflow, in days of cash use $500,000,000 / ($27,383,000 / 90) = [object Object]
- Cash and equivalents vs quarterly operating cash outflow, in days of cash use $47,256,000 / ($27,383,000 / 90) = [object Object]
News Market Reaction – ERAS
In the Jul 14 session, ERAS gained 8.94%, reflecting a notable positive market reaction. Argus tracked a peak move of +11.0% during that session. Argus tracked a trough of -15.5% from its starting point during tracking. Our momentum scanner triggered 17 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Offering Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 23 | Offering closing | Negative | -3.5% | Closed upsized stock offering with full underwriter option exercise and cash raise. |
| Jan 21 | Offering pricing | Negative | +2.4% | Priced upsized common stock offering at fixed per-share price with option. |
| Jan 20 | Proposed offering | Negative | +2.5% | Announced proposed $150 million stock offering with 30-day underwriter option. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Past equity offerings have produced mixed, slightly positive average moves, with both gains and losses around these financings.
Key Terms
underwritten public offering financial
shelf registration statement regulatory
form s-3 regulatory
prospectus supplement regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, July 13, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that it intends to offer and sell, subject to market and other conditions,
Erasca intends to use the net proceeds from the proposed offering, together with its existing cash, cash equivalents, and marketable securities, to fund the research and development of its product candidates and other development programs and for working capital and other general corporate purposes.
J.P. Morgan, Morgan Stanley, Jefferies, and Evercore ISI are acting as joint book-running managers for the proposed offering.
The securities described above are being offered by Erasca pursuant to a shelf registration statement on Form S-3, including a base prospectus, that was previously filed with the Securities and Exchange Commission (SEC) on July 13, 2026 and automatically became effective upon filing. A preliminary prospectus supplement and accompanying prospectus relating to this offering will be filed with the SEC. Copies of the prospectus supplement for this offering may be obtained, when available, by contacting J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014, or by email at prospectus@morganstanley.com; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com; and Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, NY 10055, by telephone at (888) 474-0200, or by email at ecm.prospectus@evercore.com. Electronic copies of the preliminary prospectus supplement and accompanying prospectus will also be available on the website of the SEC at http://www.sec.gov.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
About Erasca
At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of patients with cancer. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.
Forward Looking Statements
Erasca cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on our current beliefs and expectations and include, but are not limited to: our expectations regarding the completion, timing and size of the proposed offering and our intended use of proceeds therefrom, and the grant of the option to purchase additional shares. Actual results may differ from those set forth in this press release due to the risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the proposed offering, as well as risks and uncertainties inherent in our business described in our prior filings with the SEC, including under the heading “Risk Factors” in our annual report on Form 10-K for the year ended December 31, 2025, and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Contact:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
Source: Erasca, Inc.
